| 50th week of 2008 patent applcation highlights part 42 |
| Patent application number | Title | Published |
|---|
| 20080305945 | Method of Making a Phosphorus-Modified Zeolite Catalyst - A catalyst is formed from a phosphorus-containing ZSM-5-type zeolite. The ZSM-5-type zeolite has a silica/alumina molar ratio of at least 200. The phosphorus-containing ZSM-5-type zeolite also has a phosphorus content of at least 8% by weight of zeolite and has multiple phosphorus species exhibited by at least two | 2008-12-11 |
| 20080305946 | Platinum Alloy Carbon-Supported Catalysts - The instant invention relates to a platinum alloy supported electrocatalyst for gas diffusion electrode and/or in catalyst-coated membrane. | 2008-12-11 |
| 20080305947 | Highly Active Slurry Catalyst Composition - The instant invention is directed to the preparation of a slurry catalyst composition. The slurry catalyst composition is prepared in a series of steps, involving mixing a Group VIB metal oxide and aqueous ammonia to form an aqueous mixture and sulfiding the mixture to form a slurry. The slurry is then promoted with a Group VIII metal. Subsequent steps involve mixing the slurry with a hydrocarbon oil, and combining the resulting mixture with hydrogen gas (under conditions which maintain the water in a liquid phase) to produce the active slurry catalyst. | 2008-12-11 |
| 20080305948 | METHOD FOR PRODUCING CATALYTICALLY-ACTIVE MATERIALS - A method for producing a catalytically-active material having at least one base component and at least one catalytically-active component in which the at least one base component is heated to a softening or melting temperature to form a softened or molten base component. While the base component is in the softened or molten state, at least one catalytically-active component is incorporated into or onto the base component, forming the catalytically-active material. In accordance with one embodiment, a catalyst precursor is introduced into the base component and subsequently transformed to a catalytically-active component. | 2008-12-11 |
| 20080305949 | MERCURY REMOVAL SORBENT - A sorbent composition comprising a vanadium compound and a ZrO | 2008-12-11 |
| 20080305950 | Guanidinated Polysaccharides, Their Use as Absorbents and Process For Producing Same - The present invention relates to cationic, gel forming, guanidinated polysaccharides of Formula I, their use as absorbent materials, and to processes for producing same: Formula I wherein Z | 2008-12-11 |
| 20080305951 | Method for Incorporating a Functional Additive within a Porous Material - The invention relates a method for incorporating a functional additive within a porous material, which method comprises impregnating the porous material with a slurry of a nano-sized material that carries the functional additive, wherein in the slurry the weight ratio of the additive (A) and the nano-sized material (B) is in the range of from 0.01 to 1.0 (A/B). The invention further relates to a porous material obtainable by said method. | 2008-12-11 |
| 20080305952 | CROPPING SYSTEMS FOR MANAGING WEEDS - The invention provides cropping systems for managing weeds in crop environments. The cropping systems comprise, in one embodiment, transgenic plants that display tolerance to an auxin-like herbicide such as dicamba. Method for minimizing the development of herbicide resistant weeds are also provided. | 2008-12-11 |
| 20080305953 | Liquid Formulations Containing Dialkyl Sulfosuccinate And Hydroxyphenylpyruvate Dioxygenase Inhibitors - Liquid formulations containing herbicidal actives from the group of HPPD inhibitors, dialkyl sulfosuccinates, surfactants and solvents are provided. The present invention relates to liquid formulations comprising: A) one or more HPPD inhibitors, B) one or more dialkyl sulfosuccinates, C) one or more further surfactants, D) one or more solvents, E) further auxiliaries and additives, and F) one or more non-A) agrochemical actives. The liquid formulations are suitable for use in the field of crop protection. | 2008-12-11 |
| 20080305954 | Method of Controlling the Aquatic Weed Hydrilla Verticillata - A method of controlling the aquatic weed Hydrilla verticillata which comprises allowing a herbicidally effective amount of (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid (imazamox) or an agriculturally acceptable salt thereof to act on the aquatic weed and/or its aqueous habitat containing seeds or other propagating organs of said aquatic weed. | 2008-12-11 |
| 20080305955 | Spiroketal-Substituted Cyclic Ketoenols - The invention relates to novel spiroketal-substituted cyclic ketoenols of the formula (I) | 2008-12-11 |
| 20080305956 | 3-Cyclopropyl-4-(3-Thiobenzoyl) Pyrazoles And Their Use as Herbicides - What is described are 3-cyclopropyl-4-(3-thiobenzoyl)pyrazoles of the general formula (I) and their use as herbicides | 2008-12-11 |
| 20080305957 | Method for Obtaining Structural Information Concerning an Encoded Molecule and Method for Selecting Compounds - In one aspect, the present invention relates to a method for obtaining structural information about an encoded molecule. The encoded molecule may be produced by a reaction of a plurality of chemical entities and may be capable of being connected to an identifier oligonucleotide containing codons informative of the identity of the chemical entities which have participated in the formation of the encoded molecule. In a certain embodiment, primers are designed complementary to the codons appearing on the identifier oligonucleotide, and the presence, absence or relative abundance of a codon is evaluated by mixing a primer with the identifier oligonucleotide in the presence of a polymerase and substrate (deoxy)ribonucleotide triphosphates and measuring the extension reaction. In another aspect, the invention provides a method for selecting compounds which binds to a target. More specifically, the invention relates to a method in which a target associated with an oligonucleotide initially is mixed with a library of complexes, each complex comprising a display molecule and an oligonucleotide identifying said display molecule. Next, due an increased proximity, the target oligonucleotide is coupled to the identifier oligonucleotide of complexes having a display molecule with affinity towards the target. In a final stage the coupled nucleotides are analysed to deduce at least the identity of the display molecule. | 2008-12-11 |
| 20080305958 | Process for Liquid or gas Chromatography/Mass Spectrometry Based Biomolecular Screening for Drug Discovery - Methods of achieving realistic hit rates and reducing or eliminating false positive rates in medicinal compound high throughput screening are provided. The methods of the invention include chromatographic resolution, for example by liquid or gas chromatography of biological substrates and/or substrate products, followed by sensitive with mass spectrometry to measure biological activity screening to generate meaningful drug leads. The methods of the invention save significant method development and thus are directly applicable to the high throughput screening time scale while providing high accuracy and sensitivity. | 2008-12-11 |
| 20080305959 | Laser microdissection and microarray analysis of breast tumors reveal estrogen receptor related genes and pathways - About 70% to 80% of breast cancers express estrogen receptor-α (ERα), and estrogens play important roles in the development and growth of hormone-dependent tumors. Together with lymph node metastasis, tumor size and histological grade, ER status is considered one of the prognostic factors in breast cancer, and an indicator for hormonal treatment. 147 genes and 112 genes with significant P-value and having significant differential expression between ER+ and ER− tumors were identified from the LCM data set and bulk tissue data set, respectively. 61 genes were found to be common in both data sets, while 85 genes were unique to the LCM data set and 51 genes were present only in the bulk tumor data set. Pathway analysis with the 85 genes using Gene Ontology suggested that genes involved in endocytosis, ceramide generation, Ras/ERK/Ark cascade, and JAT-STAT pathway may play roles related to ER. The gene profiling with LCM-captured tumor cells provides a unique approach to characterize and study epithelial tumor cells and to gain an insight into signaling pathways associated with ER. | 2008-12-11 |
| 20080305960 | Sequences for Differential Diagnostic of Ehrlichia Ruminantium and Use Thereof - The invention provides genes that are unique either to | 2008-12-11 |
| 20080305961 | Method of Generating Translationally Active Linear Dna Molecules and Use Thereof in Array Formats - This invention provides a method for producing expressionally and translationally active linear DNA molecules that can be used as protein expression cassettes and are useful for high throughput protein expression and analysis in living cells. The method comprises a PCR amplification using two primers complementary to the sequences flanking the DNA sequence of interest, such as a cDNA, an open reading frame or a gene, that exists in expression vectors. The resultant PCR product contains a promoter, the DNA sequence of interest, and a termination sequence. The invention further provides different uses of these translationally active DNA cassettes, such as in proteome arrays. | 2008-12-11 |
| 20080305962 | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies - The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and cancer. The invention further relates to genes that are differentially expressed in tissue of cancer patients versus those of normal “healthy” tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided. The present invention relates to methods for prognosis the prediction of therapeutic success in cancer therapy. In a preferred embodiment of the invention it relates to methods for prediction of therapeutic success of combinations of signal transduction inhibitors, therapeutic antibodies, radio- and chemotherapy. The methods of the invention are based on determination of expression levels of 48 human genes which are differentially expressed prior to the onset of anti-cancer chemotherapy. The methods and compositions of the invention are most useful in the investigation of advanced colorectal cancer, but are useful in the investigation of other types of cancer and therapies as well. | 2008-12-11 |
| 20080305963 | Conductimetric biosensor device, method and system - A multi-array membrane strip biosensor device ( | 2008-12-11 |
| 20080305964 | Single-Step Platform for On-Chip Integration of Bio-Molecules - Novel compounds having a functionalized group capable of binding to a solid substrate; a photoactivatable group capable of generating a reactive group upon exposure to light and being for binding a screenable moiety; and a polymer capable of forming a monolayer on a solid substrate, and having the functionalized group and to the photoactivatable group attached thereto and processes for the preparation thereof are disclosed. Further disclosed are arrays of screenable moieties (e.g., nucleic acids, proteins, carbohydrates, substrates, chelating agents and many more) prepared using these novel compounds. | 2008-12-11 |
| 20080305965 | Classification, Diagnosis and Prognosis of Acute Myeloid Leukemia by Gene Expression Profiling - The present invention relates to method of genetic analysis for the classification, diagnosis and prognosis of acute myeloid leukemia (AML). The invention provides a method for producing a classification scheme for AML comprising the steps of a) providing a plurality of reference samples, said reference samples comprising cell samples from a plurality of reference subjects affected by AML; b) providing reference profiles by establishing a gene expression profile for each of said reference samples individually; c) clustering said individual reference profiles according to similarity; and d) assigning an AML class to each cluster. The invention further relates to a method for classifying the AML of an AML affected subject, to a method for diagnosing AML in a subject, and to a method of determining the prognosis for an AML affected subject. | 2008-12-11 |
| 20080305966 | Capture Probe Design for Efficient Hybridisation - Methods for selecting and designing optimal nucleic acid-based probe for improving the sensitivity of detection of a nucleic acid-based target are disclosed herein. The capture probes generated from these methods show a significant improvement in the sensitivity of detection. Improved probes as well as microarrays and kits comprising these probes are disclosed herewith. | 2008-12-11 |
| 20080305967 | Genetic Markers Associated with Endometriosis and Use Thereof - The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis. | 2008-12-11 |
| 20080305968 | Process for producing colloidal crystals immobilized with a polymer and colloidal crystals immobilized with a polymer - A process for producing colloidal crystals immobilized with a polymer, comprising the steps of:
| 2008-12-11 |
| 20080305969 | Ink Jet Device and Method for Producing a Biological Assay Substrate by Releasing a Plurality of Substances Onto the Substrate - The invention provides an ink jet device ( | 2008-12-11 |
| 20080305970 | Analysis Device with an Array of Focusing Microstructures - The invention relates to a device comprising a first material ( | 2008-12-11 |
| 20080305971 | Polysaccharide Treatment Fluid and Method of Treating A Subterranean Formation - A treatment fluid for treating a subterranean formation penetrated by a wellbore is formed from an aqueous medium, a diutan heteropolysaccharide having a tetrasaccharide repeating unit in the polymer backbone and a peroxide breaker. A method of treating a subterranean formation penetrated by a wellbore may be carried out by introducing the treatment fluid into the formation through the wellbore. Breaking aids or catalysts may also be used with the treatment fluid. | 2008-12-11 |
| 20080305972 | LUBRICANT COMPOSITIONS - A lubricant composition comprising a base oil comprising less than about 3% by weight of tetracycloparaffins is disclosed. Methods of making and using the lubricant composition are also disclosed. | 2008-12-11 |
| 20080305973 | Lithium Grease Composition Sealed in a Small Motor Bearing to Reduce Noise - A lithium grease composition which can be sealed in a small motor bearing to reduce noise, composed of 5-20% by weight of a thickener and 95-80% by weight of a base oil, wherein said grease composition adopts lithium soap as the thickener, which is synthesized from lithium hydroxide and a higher fatty acid with 10 to 20 carbon atoms and/or a higher hydroxyfatty acid with one or more hydroxyl groups and 10 or more carbon atoms, and the base oil includes, as a main component, a polymer ester oil (A) in which 8 or more ester groups are arranged in a comb tooth form on one side of chain molecules constituted by eight or more carbon atoms which is expressed by general formula 1: (In the formula, each of R | 2008-12-11 |
| 20080305974 | NITRATED EXTREME PRESSURE ADDITIVES AND BLENDS - This invention relates to products useful in friction-reducing extreme-pressure lubricating applications such as internal combustion engines, gear oils and applications which involve rubbing metallic moving parts. The invention includes additive blends and a process of using synergistic combinations of nitro compounds with non-chlorine containing additives such as sulfur-containing moieties and phosphorus-containing moieties. | 2008-12-11 |
| 20080305975 | ADVANCED LUBRICANT FOR THIN FILM STORAGE MEDIUM - A magnetic recording medium comprising a lubricant film comprising a photosynthesized lubricant having a single phase composition of at least a lubricant moiety and an additive moiety is disclosed. | 2008-12-11 |
| 20080305976 | Color-Stabilization of Aromachemicals - The use of at least one water-soluble sulfiting agent to reduce or prevent the discoloration of an aromachemical, odorant, flavorant or perfume component susceptible to discoloration. | 2008-12-11 |
| 20080305977 | PERFUME SYSTEMS - The present application relates to perfume systems and consumer products comprising new perfumes and/or such perfume systems, as well as processes for making and using such perfume systems and consumer products. | 2008-12-11 |
| 20080305978 | Cleaning compositions containing a hydrophilic fragrance - Cleaning compositions for hard glossy surfaces having reduced streaking and blooming based on the inclusion of a compatible fragrance or fragrance mixture therein is described. Compatible fragrance(s) are hydrophilic fragrances having a Delta value of 22 or less. The fragrance is maintained in solution in the absence of a solubilizer fragrance carrier. | 2008-12-11 |
| 20080305979 | Cleaning agent for removing solder flux and method for cleaning solder flux - The present invention provides a cleaning agent for removing the solder flux and method for cleaning the solder flux which exhibit the excellent cleaning property even at the time of cleaning a lead-free soldering flux, a high-melting-point solder flux or the like and, at the same time, exhibits the excellent rinsing property in the rinsing using an alcoholic solvent in a next step. Accordingly, the present invention provides a cleaning agent for removing the solder flux which sets a content of benzyl alcohol to a value which falls within a range of 70 to 99.9 weight % and a content of amino alcohol to a value which falls within a range of 0.1 to 30 weight % when a content of a glycol compound is below 1 weight % with respect to a total amount of the cleaning agent for removing the solder flux, and sets a content of benzyl alcohol to a value which falls within a range of 15 to 99 weight % and a content of amino alcohol to a value which falls within a range of 0.1 to 30 weight % when a content of the glycol compound falls within a range of 1 to 40 weight % with respect to a total amount of the cleaning agent for removing the solder flux. The cleaning agent for removing the solder flux is used for cleaning the lead-free solder flux and the high-melting-point solder flux or the like. | 2008-12-11 |
| 20080305980 | STABILITY OF DETERGENTS CONTAINING HYPOCHLORITE - The stability of aqueous, liquid detergents containing hypochlorite and brighteners is achieved by the use of a specific complexing agent. | 2008-12-11 |
| 20080305981 | STABILITY OF DETERGENTS CONTAINING HYPOCHLORITE - The improvement of the storage stability of aqueous, liquid detergents containing hypochlorite and brighteners is achieved by the use of cyclodextrin. | 2008-12-11 |
| 20080305982 | Benefit agent containing delivery particle - The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed. | 2008-12-11 |
| 20080305983 | Cleaning article containing hydrophilic polymers - The invention relates to a cloth that can function as a moisturizing cleanser. When the cloth is moistened with water, it works up into a warm, sudsy cleansing lotion that feels great and works well as a facial cleansing cloth. The cloth contains water, at least one surfactant and at least one hydrophilic polymer. | 2008-12-11 |
| 20080305984 | Fabric Softening Composition - A liquid fabric softening composition comprising an aqueous base, a cationic fabric softening agent, and an emulsified oil which has a refractive index at 25° C. of 1.45 or greater in an amount such that the weight ratio of oil to cationic fabric softening agent is from 1:12 to 1:1, characterised in that the D[4,3] droplet size of the emulsified oil is from 0.4 to 8 microns. | 2008-12-11 |
| 20080305985 | Isosteric Transormation - A method of generating an isosteric structure of a polypeptide at least partially containing D-amino acids from 3D-coordinates and sequence information of an L-configurated precursor having an N-terminal amino group or substituted amino group, a C-terminal carboxy group or a carboxy derivative, a backbone and L-amino acid side chains, and comprising the steps of—at least partially replacing backbone CO groups with NH groups and vice versa,—while keeping the 3D-coordinates of the precursors L-amino acid side chains, the N-terminal amino group or substituted amino group and the C-terminal carboxy group or carboxy derivative fixed. | 2008-12-11 |
| 20080305986 | Multimers of Peptides - Described are compounds useful for trimerising chemical entities, methods of trimerising chemical entities, and trimerised entities. In one aspect, the entities are peptides. | 2008-12-11 |
| 20080305987 | Sex-specific regulation of aging and apoptosis - The invention provides anti-apoptotic agents and therapies and uses thereof. Specifically, the anti-apoptotic agents and therapies involve human Xist gene, Xist RNA, Xist gene product, and antagonists and small molecule mimics of these nucleic acids and proteins. | 2008-12-11 |
| 20080305988 | V-Like Domain Binding Molecules - The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterised in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the modified VLD is improved when compared with the unmodified VLD. | 2008-12-11 |
| 20080305989 | Transdermal delivery peptides and method of use thereof - Transdermal delivery peptides for the treatment of skin diseases and/or facilitation or enhancement of transdermal delivery of pharmaceutically active agents are provided. Compositions comprising the transdermal delivery peptides and methods of therapeutic use, including the improvement of transdermal delivery of drugs or other pharmaceutically active agents, are also disclosed. Nucleic acids, expression vectors, and methods of their use, which encode the transdermal delivery peptides are disclosed. Methods are also provided for in vivo phage display for identifying further peptides with enhanced transdermal delivery capability. | 2008-12-11 |
| 20080305990 | Method of Producing Fully Carbamylated Erythropoietin - The present invention relates to a method of carbamylating an erythropoietin such that the resulting carbamylated erythropoietin has less that about 10% free primary amines on the lysines and the N-terminal amino acids, is not digested when exposed to Lys-C proteolysis, exhibits no erythropoietic activity in a TF-1 or UT-7/EPOR cell viability assay at a concentration of 1 μg/ml, and demonstrates a static sciatic index of less than about 0.65 within a Sciatic Nerve Assay. Additionally, the invention is related to pharmaceutical compositions containing carbamylated erythropoietins of the invention and the use of the pharmaceutical compositions for the treatment of conditions and diseases of excitable tissues. | 2008-12-11 |
| 20080305991 | Factor IX: remodeling and glycoconjugation of factor IX - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | 2008-12-11 |
| 20080305992 | Glycopegylated erythropoietin - The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 2008-12-11 |
| 20080305993 | Use of C1 Inhibitor for the Prevention of Ischemia-Reperfusion Injury - The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke. | 2008-12-11 |
| 20080305994 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye - A composition for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition or an opthalmologic disorder that has an etiology in inflammation comprises an inhibitor of activity of poly(ADP-ribose) polymerase (“PARP”). The composition can also include a modulator of pro-inflammatory gene expression. | 2008-12-11 |
| 20080305995 | Royal Jelly Peptide and Composition Containing the Same - A royal jelly peptide which has a function as a queen bee's attraction cofactor and can enhance the biological defense system of an animal (an immunopotentiating effect); and a composition containing the same. | 2008-12-11 |
| 20080305996 | Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same - The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 2008-12-11 |
| 20080305997 | Modulation Of Cd4+ T Cell Responses By A Tick Saliva Protein, Salp15 And Polypeptides Derived Therefrom - Salp15, biologically functional equivalents and fragments thereof, and nucleic acid molecules encoding the same are disclosed. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed. Salp15 gene products and Salp15 polypeptide fragments have biological activity in modulating CD4+ T cell activation through specific binding to CD4. Thus, therapeutic methods involving modulating T cell activation using Salp15 and biologically active polypeptide fragments thereof are also disclosed. The specific binding of Salp15 and fragment peptides thereof to CD4 can inhibit HIV infection of T cells, and thus methods of using Salp15 for inhibiting HIV infection are also disclosed. Screening methods for selecting substances having an ability to modulate activation of T cells are also disclosed. | 2008-12-11 |
| 20080305998 | Ligand to GPR8 and DNA thereof - The present invention aims at providing a ligand to GPR8, its DNA, etc., and more particularly, a polypeptide capable of binding to GPR8 or its amides or esters, or salts thereof, as well as its DNA, etc. | 2008-12-11 |
| 20080305999 | Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia - Vascular endothelial growth factor (VEGF) has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g. using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered. | 2008-12-11 |
| 20080306000 | Three-Dimensional Structures of TALL-1 and its Cognate Receptors and Modified Proteins and Methods Related Thereto - Disclosed are TALL-1 and TALL-1 receptor protein homologues (agonists and antagonists) designed based on the three-dimensional structure of sTALL-1, eBCMA and eBAFF-R; agonist homologues of APRIL; methods of using wild-type APRIL to inhibit the activity of TALL-1; compositions comprising such homologues, nucleic acid molecules encoding such homologues, and therapeutic methods of using such compounds and compositions. Also disclosed are crystalline complexes of sTALL-1 and sTALL-1 in complex with either BCMA or BAFF-R; models of three-dimensional structures of such crystalline complexes and related structures, methods of drug design using any portion of such structures; methods of design and/or identification of regulatory peptides derived from the such structures; compounds identified by drug design using such structures; and the use of such compounds in therapeutic compositions and methods. | 2008-12-11 |
| 20080306001 | TRANSCRIPTIONAL MODULATION OF EXTRACELLULAR MATRIX (ECM) OF DERMAL FIBROBLASTS - The present invention includes peptides, compositions as well as their use for the prevention or treatment of various age related or pathological conditions of skin or other tissues including skin wrinkles, wounds, different types of fibrosis and methods of reconstructing different tissues such as techniques used in regenerative medicine. The invention further includes peptide mimetics and methods of use including interfering with transcriptional complexes characteristic of fibroblasts of aged skin and stimulating synthesis of structural components of extracellular matrix. | 2008-12-11 |
| 20080306002 | Combination Therapy for Preventing Angiogenesis - The present invention is directed to a combination therapy for inhibiting angiogenesis in a subject having, or at risk of having, an angiogenic disease/disorder. The method comprises both administering to the mammal an inhibitor of HIF-I and administering a second compound or agent that inhibits angiogenesis such as an inhibitor of IL-8, VEGF, angiopoietins, EGF, FGF, TGF, G-CSF, or PDGF. Administration of an inhibitor of hypoxia inducible factor-1 (HIF-I) in combination with an inhibitor of interleukin 8 (IL-8) is particularly useful for treatment of colon cancer, lung cancer, pancreatic cancer, and breast cancer. | 2008-12-11 |
| 20080306003 | Novel Compositions and Methods for Promoting, Inhibiting and Detecting Protein Entry Into Cells - The invention features methods for identifying compounds that inhibit cell death, and methods for identifying compounds that promote cell death, by blocking or accelerating, respectively, the translocation of the catalytic domain of toxins or transcription factors through the endosomal membrane into the cytosol of a cell. Also featured are methods for inhibiting cell death that include the administration of polypeptides that include a toxin consensus sequence recognized by one or more components of the cytosolic translocation factor complex. | 2008-12-11 |
| 20080306004 | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides - The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. In particular, the invention relates to novel stem cell growth factor-like polypeptides, including novel proteins named SCGF3248Fk081_aa2, SCGF3248Fk081_aa1, SCGFFk081_aa3, and SCGF323401Fe131_aa1. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides. | 2008-12-11 |
| 20080306005 | TREATMENT OF BONE DISORDERS WITH SKELETAL ANABOLIC DRUGS - Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety. | 2008-12-11 |
| 20080306006 | MicroRna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provide methods of identifying inhibitors of tumorigenesis. | 2008-12-11 |
| 20080306007 | AGENTS FOR PROPHYLAXIS OR TREATMENT OF NEUROLOGICAL RELATED DISEASES AND CONDITIONS - Inhibitors of syndapin I binding to dynamin I (DynI) are provided. Examples include mimetics of a region of DynI including the serine residues S774 and S778 or phosphorylatable amino acids in homologous positions. Typically, the mimetics exclude or do not imitate at least one phosphorylation site provided by the serine residues or phosphorylatable amino acids. Peptide fragment inhibitors comprising or consisting of this region of DynI are also described. The inhibitors have application in the prophylaxis or treatment of neurological diseases or conditions. The inhibitors can also be used to inhibit neuronal cell vesicle trafficking and synaptic signal transmission. | 2008-12-11 |
| 20080306008 | Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 2008-12-11 |
| 20080306009 | Immunoregulatory compositions - The invention relates to compounds exhibiting immunoregulatory activity as determined by measuring the compound's ability to modulate production of NO by a cell. Preferred compounds include or consist of a sequence | 2008-12-11 |
| 20080306010 | VACCINE COMPOSITION CONTAINING IRRADIATED OVALBUMIN FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE - The present invention relates to a vaccine composition for the prevention and treatment of allergic disease comprising irradiated ovalbumin as an effective ingredient, more precisely a method for preparing an immunogen of a vaccine for the prevention and treatment of allergic disease using the irradiated ovalbumin which is separated and purified from the albumen of an egg, a vaccine composition for the prevention and treatment of allergic disease comprising the irradiated ovalbumin as an effective ingredient, and a method for the prevention and treatment of allergic disease using the vaccine comprising the irradiated ovalbumin. In the mouse vaccinated with the irradiated ovalbumin, humoral and cell mediated immune responses were both reduced, suggesting that allergic reaction was inhibited. Thus, the composition of the present invention can be effectively used as a vaccine for the prevention and treatment of allergic disease. | 2008-12-11 |
| 20080306011 | Method of Controlling the Proliferation of Vascular Endothelial Cells and Inhibiting Lumen Formation - [PROBLEMS] To find out a specific rare sugar having effects of inhibiting the proliferation of vascular endothelial cells and lumen formation and utilize these effects. To provide this rare sugar as a preventive/remedy for diseases with angiogenesis, a cosmetic or a functional food. | 2008-12-11 |
| 20080306012 | Polysaccharide-Derived Nitric Oxide-Releasing Carbon-Bound Diazeniumdiolates - The invention relates to compounds capable of releasing nitric oxide wherein the compounds comprise a saccharide and at least one nitric oxide-releasing diazeniumdiolate [N | 2008-12-11 |
| 20080306013 | ILLUDIN ANALOGS USEFUL AS ANTITUMOR AGENTS - The present invention provides illudin analogs of the general formula (I): | 2008-12-11 |
| 20080306014 | Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial - The present invention provides agents which are capable of regulating the function of a micro-RNA component which can be used to regulate an AChE-associated biological pathway. In addition, the present invention provides methods and pharmaceutical compositions for the treatment of various pathologies related to AChE-associated biological pathways such as apoptosis, aberrant cholinergic signaling, abnormal hematopoietic proliferation and/or differentiation, cellular stress, exposure to inflammatory response-inducing agents, and/or exposure to organophosphates or other AChE inhibitors. | 2008-12-11 |
| 20080306015 | siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PCSK9. | 2008-12-11 |
| 20080306016 | Nucleic Acid Functionalized Nanoparticles for Therapeutic Applications - Materials and Methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle. | 2008-12-11 |
| 20080306017 | Microrna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Lung Cancer - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer. The invention also provide methods of identifying anti-lung cancer agents. | 2008-12-11 |
| 20080306018 | Micro-Rna Expression Abnormalities of Pancreatic, Endocrine and Acinar Tumors - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent. | 2008-12-11 |
| 20080306019 | Dopamine Receptor Agonists in the Treatment and Prevention of Hiv-Induced Dementia - Provided herein is a method of protecting a neuron from dysfunction induced by an HIV neurotoxin, comprising contacting the cell with a therapeutically effective dose of a dopamine D1 receptor agonist. Also provided is a method of treating or preventing HIV-1 associated dementia (HAD) in a subject in need of such treatment or prevention, comprising administering to the subject a therapeutically effective dose of a dopamine D1 receptor agonist and estrogenic compound. | 2008-12-11 |
| 20080306020 | Skin-Protecting Alkalinity-Controlling Composition and the Use Thereof - A skin-protecting alkalinity-controlling composition comprises one or more carboxylic acid polysaccharides. Said compositions are capable of providing buffering, and thus avoiding a major increase in the pH of an aqueous system and/or are capable of reducing the pH of aqueous systems, in which alkalinity is formed as a result of chemical and/or biological reactions. The compositions may be used in personal care products, such as skin creams and lotions, hygiene products, wound care products, fabric treating products etc. | 2008-12-11 |
| 20080306021 | Cosmetic Preparation Comprising Hyaluronic Acid - The present invention relates to cosmetic preparations with an active substance combination of hyaluronic acid and saponins. | 2008-12-11 |
| 20080306022 | Agent for Applying to Mucosa and Method for the Production Thereof - An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying property in a mucosal epithelial layer is provided, said agent for application to mucosa containing glycosaminoglycan (GAG) into which a hydrophobic group is introduced via a binding chain, as an active ingredient. | 2008-12-11 |
| 20080306023 | Derivatives of Hyaluronic Acid, Their Preparation Process and Their Uses - The present invention relates to the use of a compound having the formula (I) wherein: n represents an integer varying from 720 to 6 200, and i varies from 1 to n, R | 2008-12-11 |
| 20080306024 | METHOD FOR MICRO-INCISION CATARACT SURGERY, A METHOD OF EVALUATION OF A VISCOELASTIC MATERIAL , A COMPOSITION FOR EVALUATION OF A VISCOELASTIC MATERIAL AND A METHOD FOR EVALUATION USING THE COMPOSITION - A method for micro-incision cataract surgery, wherein a solution containing hyaluronic acid having a weight average molecular weight of from 600,000 to 1,200,000 or a salt thereof is injected into the anterior chamber, and flow rate of a perfusion liquid in the anterior chamber is set to about be 35 to 40 mL/min or less, a method for evaluating retentivity of a viscoelastic material, which uses a device consisting of a micro-flare ultrasonic chip arranged in water, a sleeve which covers said chip and a hollow cylinder into which said chip is inserted, and a composition for evaluation of retentivity of a viscoelastic material, which comprises at least said viscoelastic material and a fluorescent granule, are provided. | 2008-12-11 |
| 20080306025 | N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE - The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic administration to a mammalian subject, as well as a method of administering an effective amount of such a composition for alleviating or improving a condition, disorder, symptom or syndrome associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system. | 2008-12-11 |
| 20080306026 | Capsule Formulation - An encapsulated composition of (a) a pesticide at least active via ingestion that is photolabile, and (b) at least one photoprotectant, wherein the encapsulating polymeric barrier is base triggerable is disclosed. A method for controlling damage of a material by a pest by the use of such encapsulated compositions is likewise disclosed. The composition as disclosed gives protection for beneficial arthropods and reduces workers exposure. | 2008-12-11 |
| 20080306027 | Fluoroalkoxycombretastatin Derivatives, Method For Producing the Same and Use Thereof - Combretastatin derivatives of formula (I), preparation and use thereof are disclosed, wherein: R | 2008-12-11 |
| 20080306028 | Erianin Salts, Their Preparation Methods and Pharmaceutical Compositions Containing the Same - This invention relates to a kind of Erianin salt and the preparing process thereof. The said Erianin salt is a compound with the following general formula (I), wherein R is the salt formed by monobasic acid radical of inorganic oxacid combining with metals, ammonium salts, organic amine. This invention also relates to a pharmaceutical composition comprising Erianin salt. Compared with Erianin, the said Erianin salt has far better solubility, which can improve the bioavailability and show better antineoplastic efficacy. | 2008-12-11 |
| 20080306029 | Prevention, Treatment, and Amelioration of Radiation Induced Enteritis - The present invention provides a new method of ameliorating and/or treating enteritis induced by radiation therapy, alone or in combination with other therapies, for the treatment of, for example, gastrointestinal malignancies, including colorectal, appendiceal, anal, or small bowel cancers; urogenital malignancies, including prostate, ladder, testicular, or penile cancers; gynecologic malignancies, including cervical, endometrial, ovarian, vaginal, or vulvar cancers; or osteogenic and other sarcomatous malignancies in which pelvic structures are involved, comprising the administration of a therapeutically effective amount of balsalazide to a patient in need thereof. | 2008-12-11 |
| 20080306030 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release - The present invention is directed to methods of enhancing insulin release, GLP-1 release, and insulin sensitivity, methods of increasing insulin gene expression, methods of decreasing gastric secretion and emptying and glucagons secretion, and methods of inhibiting food intake, and methods of treating diabetes mellitus, insulin resistance syndrome, hyperglycemia, and obesity comprising administering to a subject an effective amount of a TRPM5 inhibitor. | 2008-12-11 |
| 20080306031 | Methods of Inhibiting Poxvirus Growth - This disclosure ascribes new functions to derivatives of tetralin, anthraquinone, naphthylamine, tri-amino-pyrimidine, xanthen-3-one, and/or cinnamic acid (including, for example, NSC270718R, NSC117285R, NSC170008Y, NSC306711P, NSC119913X, NSC119915Z, NSC119911V, NSC119910U, NSC128437O, NSC125908P, NSC9600Q, or NSC13778J, each obtained from the Structure Diversity Set, National Institutes of Health, National Cancer Institute, Developmental Therapeutics Program). These compounds are shown to be effective inhibitors of viral essential protein kinases (such as poxvirus B1 and/or F10 protein kinases). Exemplary chemical structures for viral protein kinase (VPK) inhibitors are provided, as are methods of using such compounds, for instance, to inhibit VPK activity and/or poxvirus growth, and/or for the treatment of poxvirus infection. Also provided are pharmaceutical compositions including disclosed VPK inhibitors. | 2008-12-11 |
| 20080306032 | 7-Phenyl-Substituted Tetracycline Compounds - 7-phenyl-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described. 7-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described. | 2008-12-11 |
| 20080306033 | Use of Non-Steroidal Anti-Inflammatory Drugs by Inhalation in the Treatment of Acute and Chronic Bronchitis - This invention claims the use of non-steroidal anti-inflammatory drugs, and in particular lysine acetylsalicylate, delivered by nebuliser, to treat non-asthmatic bronchitis, namely acute bronchitis, chronic bronchitis, emphysema and chronic obstructive pulmonary disease. | 2008-12-11 |
| 20080306034 | Method of Administering a Therapeutic - The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a hormonal treatment such as a combined estrogen/progestin therapeutic which specifically includes an oral contraceptive that at least partially prevents or compensates for an endometriosis related symptom. | 2008-12-11 |
| 20080306035 | Methods and Compositions for Treating Female Infertility Using Clomiphene - The present invention relates to the use of compositions comprising clomiphene for treating female infertility. The invention is also directed to a regimen of treatment for female infertility using trans-clomiphene, a mixture of cis- and trans-clomiphene, and cis-clomiphene. | 2008-12-11 |
| 20080306036 | Triphenylethylene Compounds Useful as Selective Estrogen Modulators - Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation. | 2008-12-11 |
| 20080306037 | Product for Use in the Prevention and Treatment of Cardiovascular Diseases, Cancer and Chronic Inflammatory Diseases - The invention relates to a product that contains at least lycopene and oleic acid together with antioxidants of natural origin, such as β-carotenes, retinol, phytosterols, tyrosol and fatty acids, which is administered orally and which is specially indicated in the prevention of cardiovascular disease and in pathologies mediated by an anomalous activation of factor NF-κB, such as chronic inflammatory diseases and certain types of cancer, including colon cancer and prostate cancer. | 2008-12-11 |
| 20080306038 | Compositions and Methods for Modulating Inflammation Using Fluoroquinolones - Compositions for modulating an inflammation comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating an inflammation comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating an ocular or ophthalmic inflammation, including uveitis, vernal keratoconjunctivitis, or inflammation associated with contact lens-associated corneal infiltrates. | 2008-12-11 |
| 20080306039 | Loteprednol Etabonate Aqueous Suspension - An aqueous suspension containing loteprednol etabonate wherein sedimented particles are detached easily from the container and adhesion of sedimented particles to the container and block formation are inhibited so that redispersion has been improved is provided. A method for improving redispersibility of loteprednol etabonate contained in the aqueous suspension is also provided. | 2008-12-11 |
| 20080306040 | Antibacterial amide macrocycles VII - The invention relates to antibacterial amide macrocycles and methods for their preparation, their use for the treatment and/or prophylaxis of diseases as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially bacterial infections. | 2008-12-11 |
| 20080306041 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use - The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one heterocyclic nitric oxide donor group, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension and (n) treating ophthalmic disorders. The cardiovascular compounds are preferably β-adrenergic antagonists, angiotensin-converting enzyme (ACE) inhibitors, anti-hyperlipidemic compounds, and antithrombotic and vasodilator compounds. The heterocyclic nitric oxide donor groups are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. | 2008-12-11 |
| 20080306042 | Triazole Derivatives - Novel triazole derivatives are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumours. | 2008-12-11 |
| 20080306043 | Sabcomeline Alone or Combined with a Mood Stabilising or Antimanic Agent to Treat Bipolar Disorders - The invention relates to the use of sabcomeline or a pharmaceutically acceptable salt thereof in monotherapy for the treatment of bipolar disorder or mania or and to adjunctive and simultaneous combination therapies for the treatment of bipolar disorder or mania in which sabcomeline or a pharmaceutically acceptable salt thereof and at least one other mood stabilizing or antimanic agent are administered adjunctively or simultaneously. The invention provides methods of treatment of bipolar disorder or mania utilizing such monotherapy and such adjunctive or simultaneous therapeutic combination therapies, therapeutic combinations for use therein and pharmaceutical compositions comprising them. | 2008-12-11 |
| 20080306044 | SPIROBENZOAZEPANES AS VASOPRESSIN ANTAGONISTS - The present invention is directed to a compound of Formula (I) or a form thereof: | 2008-12-11 |
